HCC | Clinical

Second-Line Pembrolizumab Shows Continued OS and PFS Improvement in Advanced HCC

January 18, 2021

In patients with previously treated advanced hepatocellular carcinoma (HCC), single-agent pembrolizumab (Keytruda) maintained numerical improvement in survival (OS), updated findings randomized phase 3 KEYNOTE-240 trial show.

Survival Benefit Maintained With Atezolizumab Plus Bevacizumab in Advanced HCC

January 17, 2021

Results from the phase 3 IMbrave150 clinical trial showed that the combination of atezolizumab and bevacizumab continued to demonstrate improvement in survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.